Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
REDWOOD CITY, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cance...
What is the current shareholder composition and are there any upcoming lock‑up expirations or insider sales that could affect share supply?
How will the expansion of the BDC-4182 trial to other countries affect cash burn and operational risk?
What are the potential regulatory hurdles for the next‑generation Boltbody™ ISAC platform, and how might they affect timeline and valuation?
27 days ago